CVR number 66351912
Industry 46.4610 Wholesale of pharmaceutical goods

PFIZER ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  1.6% 1.6% 2.1% 2.6% 0.9%  
Credit score (0-100)  75 75 66 60 89  
Credit rating  A A A BBB A  
Credit limit (mDKK)  0.9 0.9 0.1 0.0 32.1  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Net sales  422 320 1,581 2,300 965  
Gross profit  422 320 1,581 243 239  
EBITDA  30.0 24.3 140 119 49.6  
EBIT  30.0 24.3 140 119 49.6  
Pre-tax profit (PTP)  19.0 29.0 106.1 119.2 57.4  
Net earnings  19.0 29.0 106.1 92.0 43.5  
Pre-tax profit without non-rec. items  30.0 24.3 140 119 57.4  
 
See the entire income statement

Balance sheet (mDKK) 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Tangible assets total  0.0 0.0 0.0 0.3 0.3  
Shareholders equity total  443 302 483 395 345  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  688 435 784 1,331 637  
Net Debt  0.0 0.0 0.0 -1.5 -0.7  
 
See the entire balance sheet

Volume 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Net sales  422 320 1,581 2,300 965  
Net sales growth  -8.3% -24.1% 394.0% 45.5% -58.0%  
Gross profit  422 320 1,581 243 239  
Gross profit growth  -8.3% -24.1% 394.0% -84.6% -1.8%  
Employees  136 107 119 119 116  
Employee growth %  -0.7% -21.3% 11.2% 0.0% -2.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  688 435 784 1,331 637  
Balance sheet change%  10.8% -36.8% 80.3% 69.8% -52.1%  
Added value  30.0 24.3 139.7 119.5 49.6  
Added value %  7.1% 7.6% 8.8% 5.2% 5.1%  
Investments  0 0 0 0 -0  
Net sales trend  -1.0 -2.0 1.0 2.0 -1.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
EBITDA %  7.1% 7.6% 8.8% 5.2% 5.1%  
EBIT %  7.1% 7.6% 8.8% 5.2% 5.1%  
EBIT to gross profit (%)  7.1% 7.6% 8.8% 49.1% 20.8%  
Net Earnings %  4.5% 9.1% 6.7% 4.0% 4.5%  
Profit before depreciation and extraordinary items %  4.5% 9.1% 6.7% 4.0% 4.5%  
Pre tax profit less extraordinaries %  7.1% 7.6% 8.8% 5.2% 5.9%  
ROA %  4.6% 4.3% 22.9% 11.3% 5.8%  
ROI %  5.6% 6.5% 35.3% 26.9% 14.6%  
ROE %  4.4% 7.8% 27.0% 21.0% 11.8%  

Solidity 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Equity ratio %  32.3% 34.9% 31.0% 29.7% 54.1%  
Relative indebtedness %  57.4% 40.7% 18.8% 40.4% 26.2%  
Relative net indebtedness %  57.4% 40.7% 18.8% 40.4% 26.1%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% -1.2% -1.4%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Quick Ratio  0.0 0.0 0.0 1.2 2.0  
Current Ratio  0.0 0.0 0.0 1.4 2.5  
Cash and cash equivalent  0.0 0.0 0.0 1.5 0.7  

Capital use efficiency 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Trade debtors turnover (days)  0.0 0.0 0.0 5.6 51.2  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 57.8% 66.0%  
Net working capital  -242.1 -130.3 -297.2 400.3 384.4  
Net working capital %  -57.4% -40.7% -18.8% 17.4% 39.8%  

Employee efficiency 
2019
2019/11
2020
2020/11
2021
2021/11
2022
2022/11
2023
2023/11
Net sales / employee  3 3 13 19 8  
Added value / employee  0 0 1 1 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 1 1 0  
EBIT / employee  0 0 1 1 0  
Net earnings / employee  0 0 1 1 0